

DAFTAR PUSTAKA

1. Indonesian Renal Registry (IRR). 2018. 11th Report of Indonesian Renal Registri.
2. Laporan Rumah Sakit – RSUP. Dr. M. Djamil Padang. [cited 2024 Feb 25]. Available from: <https://rsdjamil.co.id/laporan-rumah-sakit/>
3. Li G, Chen Y, Hu H, Liu L, Hu X, Wang J, *et al.* Association Between Age-Related Decline of Kidney Function and Plasma Malondialdehyde. *Rejuvenation Research*. 2012;15(3):257–64.
4. Fredrik K, Kraaijenhof JM, von Herrath M, Hovingh GKK, von Scholten BJ. Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. *Expert Review of Clinical Immunology*. 2022 Mar 1;18(4):377–89.
5. Obaida Istanbuly, Belcher J, Tabinor M, Solis-Trapala I, Lambie M, Davies SJ. Estimating the association between systemic Interleukin-6 and mortality in the dialysis population. Re-analysis of the global fluid study, systematic review and meta-analysis. *BMC Nephrology*. 2023 Oct 26;24(1).
6. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. *Nephrology*. 2012;17:311-21.
7. White S, Lin L, Hu K. 2020. NF- κ B and tPA Signaling in Kidney and Other Diseases. *Cells*. 9(6):1348.

8. Sterner R.M., Hartono S.P., Grande J.P. The Pathogenesis of Lupus Nephritis. *J. Clin. Cell. Immunol.* 2014; 5:205.
9. Kiryluk K., Novak J. The genetics and immunobiology of IgA nephropathy. *J. Clin. Investig.* 2014; 124:2325–32.
10. Donnahoo K.K., Shames B.D., Harken A.H., Meldrum D.R. Review article: The role of tumor necrosis factor in renal ischemia-reperfusion injury. *J. Urol.* 1999; 162:196–203.
11. Eftimovska N, Stojceva-Taneva O, Polenakovic M. Slow progression of chronic kidney disease and what it is associated with. *Prilozi.* 2008;29(1):153–65.
12. Mallamaci F, Tripepi G. Risk Factors of Chronic Kidney Disease Progression: Between Old and New Concepts. *Journal of Clinical Medicine.* 2024;13(3):678.
13. Osman F, Haldar S, Henry CJ. Effects of Time-Restricted Feeding during Ramadan on Dietary Intake, Body Composition and Metabolic Outcomes. *Nutrients.* 2020 Aug 17;12(8):2478.
14. Madkour MI, El-Serafi AT, Jahrami HA, Sherif NM, Hassan RE, Awadallah S, et al. 2019. Ramadan diurnal intermittern fasting modulates SOD2, TFAM, Nrf2, and sirtuins (SIRT, SIRT3) gene expressions in subjects with overweightand obesity. *Diabetes res;* 1–11
15. Zouhal H, Bagheri R, Larky DA, Wong A, Triki R, Hackney AC, et al. 2020. Effects of Ramadan Intermittent Fasting, on Inflammatory and biochemical biomarkers in male with obesity. *J Physiol Behav;* (1):113090

16. Faris E, Kacimi S, Al-Kurd R, Fararjh MA, Bustanji YK, et al. 2012. Intermittent fasting during Ramadan attenuates proinflammatory cytokines and immune cells in healthy subjects. *Nutr Res*; 32(12):947–55
17. Megahed AF, El Kannishy G, Sayed AN. 2019. Status of fasting in ramadan of chronic hemodialysis patients all over egypt: A multicenter observational study. *Study J kidney dis transpl* 30(2);339–49.
18. Adanan NIH, Adnan W, Khosla P, Karupiah T, Daud ZAM. 2021. Exploring the experience and perceptions of haemodialysis patients observing ramadan fasting: a qualitative study. *BMC nephrol* 22(1):48.
19. Wan MD Adnan. Zaharan NL, Wong MH, Lim SK. 2014. The effect of intermittent fasting during the month of ramadan in chronic haemodialysis patients in a tropical climate country. *Plos One* e114262.
20. Karatas A, Canakci E, Arici YK, Kaya M, Sayim B. The effect of fasting during ramadan on the kidney functions of stage III-IV chronic kindey disease patients. *Pak J Med Sci*. 2021;37(4):972–978.
21. Erwindo. Pengaruh Puasa Ramadan Terhadap Kadar Interleukin-6 Dan Malnutrition Inflammation Score (MIS) Pada Pasien Hemodialisis Rutin. Jakarta; Sp-2 Ilmu Penyakit Dalam. 2022: T22196fk.
22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012. Clinical Practice Guideline for The Evaluation and Management of Chronic Kidney Disease. *Kidney int Suppl*. 2013;3(1):1-150
23. Samak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a

statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation*.2003;108:2154-69

24. Rutkowski P, Slominska EM, Szolkiewicz M, Aleksandrowicz E. Smolenski RT, Wolyniec W, *et al*. Relationship between uremic toxins and oxydative stress in patients with chronic renal failure. *Scand J Urol Nephrol*. 2007;41(3):243-8
25. Urooj A, Pai K, Shivanna LM, Anandan S, Thamtry AN, Siraj SF. Effect of ramadan fasting on body composition, biochemical profile, and antioxidant status in a sample of healthy individuals. *Int J Endocrinol Metab*. 2020;18(4):e107641
26. Carter S., Clifton P. M., Keogh J. B. The effects of intermittent compared to continuous energy restriction on glycaemic control in type 2 diabetes: a pragmatic pilot trial. *Diabetes Research and Clinical Practice*. 2016(1); 122:106–112.
27. Liubingli BJ. Energy supply and physiological changes under starvation. *Chinese Journal of Coal Industry Medicine*2005;8(6):547–548.
28. Gabel K, Hoddy KK, Haggerty N. Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: a pilot study. *The Journal of Nutrition, Health and Aging*. 2018;4(4):345–353.
29. Catenacci VA, Pan Z, Ostendorf D. A randomized pilot study comparing zero-calorie alternate-day fasting to daily caloric restriction in adults with obesity. *Obesity (Silver Spring)*. 2016;24(9):1874–1883.

30. Patterson, R.E. and Sears, D.D. Metabolic Effects of Intermittent Fasting. *Annual Review of Nutrition*. 2017; 37(1), pp.371–393.
31. Longo, Valter D. and Mattson, Mark P. Fasting: Molecular Mechanisms and Clinical Applications. *Cell Metabolism*, 2014: pp181–192.
32. Michalsen A, Schlegel F, Rodenbeck A. Effects of short-term modified fasting on sleep patterns and daytime vigilance in non-obese subjects: results of a pilot study. *Nutrition and Metabolism*. 2003;47(5):194–200.
33. Michalsen A. Prolonged fasting as a method of mood enhancement in chronic pain syndromes: a review of clinical evidence and mechanisms. *Current Pain and Headache Reports*. 2010;14(2):80–87.
34. de Cabo, R. and Mattson, M.P. 2019. Effects of Intermittent Fasting on Health, Aging, and Disease. *New England Journal of Medicine*, 381(26); 2541–51
35. Afandi B, Alarouj M, Shaikh S. Risk stratification of people with diabetes before ramadan. Brussels, Belgium: International Diabetes Federation and DAR International Alliance; 2021.
36. Schrauben, S.J., Jepson, C., Hsu, J.Y., Wilson, F.P., Zhang, X., Lash, J.P., Robinson, B.M., Townsend, R.R., Chen, J., Fogelfeld, L., Kao, P., Landis, J.R., Rader, D.J., Hamm, L.L., Anderson, A.H. and Feldman, H.I. Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study. *BMC Nephrology*. 2019;60.

37. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. *Pediatric Nephrology*. 2009 Aug;24(8):1445–52.
38. Petreski T, Piko N, Ekart R, Hojs R, Bevc S. Review on Inflammation Markers in Chronic Kidney Disease. *Biomedicines*. 2021 Feb 11;9(2):182.
39. Roky R, Houti I, Moussamih S, Qotbi S, Aidil N. Physiology and chronobiological changes during ramadan intermitten fasting. *Ann Nutr Metab*. 2004;48(4):296–303
40. Mushtaq R, Akram A, Mushtaq R, Khwaja S, Ahmed S. The role of inflammatory markers following Ramadan Fasting. *Pak J Med Sci*. 2019;35(1):77–81
41. Filiopoulos V, Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. *Inflamm Allergy Drug Targets*. 2009;8(5):369-82.
42. Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease *Blood Purif*. 2015;39(1-3):84-92.
43. Panzer U, Schneider A, Steinmetz OM, Wenzel U, Barth P, Reinking R, Becker JU, Harendza S, Zahner G, Fischereeder M, Krämer BK, Schlöndorff D, Ostendorf T, Floege J, Helmchen U, Stahl RA. The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. *Kidney Int*. 2005; 67:75–81
44. Liao TD, Yang XP, Liu YH, Shesely EG, Cavaasin MA, Kuzie WA, Pagano PJ, Carretero OA. Role of inflammation in the development of renal damage and

- dysfunction in angiotensin II-induced hypertension. *Hypertension*. 2008; 52:256–263.
45. Hayden MS, Ghosh S. 2011. NF- κ B in immunobiology. *Cell Research* 11(21):223–244.
46. Lee D, Goldberg AL. 2015. Muscle Wasting in Fasting Requires Activation of NF- κ B and Inhibition of AKT/Mechanistic Target of Rapamycin (mTOR) by the Protein Acetylase, GCN5. *The Journal of Biological Chemistry* Vol. 290(5): 30269–79.
47. Mitchell S, Vargas J, Hoffmann A. 2016. Signaling via the NF κ B system. *Wiley Interdiscip Rev Syst Biol Med*. 8(3): 227–241.
48. Liu T, Zhang L, Joo D, Sun SC. NF- κ B signaling in inflammation. *Signal transduction and targeted therapy*. 2017;2: 17023.
49. Sanz AB, Sanchez-Niño MD, Ramos AM, Moreno JA, Santamaria B, Ruiz-Ortega M, *et al*. NF-kappaB in renal inflammation. *Journal of the American Society of Nephrology: JASN*. 2010 Aug;21(8):1254–62.
50. Heloísa M, Rildo Aparecido Volpini, Carolina A, Mariana Moura Nascimento, Rita D, Antônio Carlos Seguro, *et al*. Administration of a single dose of lithium ameliorates rhabdomyolysis-associated acute kidney injury in rats. *PLOS ONE*. 2023 Feb 16;18(2):679–9.
51. Filiopoulos V, Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. *Inflamm Allergy Drug Targets*. 2009;8(5):369-82

52. Pecoits FR, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. *Nephrol Dial Transplant*. 2003;18(6):1042–5.
53. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. *Nature Reviews Immunology*. 2015;15(6):335–49.
54. Thandavan T. Interleukin 6 Strongly Correlates with Malnutrition Inflammation Score and it is Strong Predictor for Mortality in Hemodialysis Patients. *Urology & Nephrology Open Access Journal*. 2015;2(2)
55. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, *et al*. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. *Kidney Int*. 2010;77(6):550-6.
56. Beberashvili I, Sinuani I, Azar A, Yasur H, Shapiro G, Feldman L, *et al*. IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients. *Clin J Am Soc Nephrol*. 2011;6(9):2253-63
57. Hasuike Y, Nonoguchi H, Ito K, Naka M, Kitamura R, Nanami M, *et al*. Interleukin-6 is a predictor of mortality in stable hemodialysis patients. *Am J Nephrol*. 2009;30(4):389-98.
58. Dai L, Golembiewska E, Lindholm B, Stenvinkel P. End-Stage Renal Disease, Inflammation and Cardiovascular Outcomes. *Contrib Nephrol*. 2017;191(3):2–43.
59. Filho RP, Barany P, BengtLindholm, Heimbürger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment.

European Renal Association-European Dialysis and Transplant Association.
2002;1(7):1684-8

60. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B. Mortality malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? *Kidney Int Suppl*. 2002(80):103-8.
61. Kovesdy, C.P. 2022. Epidemiology of Chronic Kidney disease: an Update 2022. *Kidney International Supplements*, 12(1), pp.7–11.
62. Centers for Disease Control and Prevention Chronic kidney disease (CKD) surveillance system: 2021. <https://nccd.cdc.gov/ckd/default.aspx> diakses 30 Mei, 2025.
63. Siregar S, Karim M, Kunci-Penyakit K, Kronik G. CHARACTERISTICS OF CHRONIC KIDNEY DISEASE PATIENTS TREATED IN HOSPITAL HASAN SADIKIN BANDUNG IN 2018. *Jurnal Pengabdian kepada Masyarakat*. 4(4):82–5.
64. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. 2016. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. Remuzzi G, editor. *PLOS ONE* 12(1), kp.1–39.
65. Hustrini NM, Susalit E, Rotmans JI. Prevalence and risk factors for chronic kidney disease in Indonesia: An analysis of the National Basic Health Survey 2018. *Journal of Global Health*. 12(1), mn.7–22.
66. Gatwood J, Chisholm-Burns M, Davis R, Thomas F, Praveen Potukuchi, Hung A, et al. Evidence of chronic kidney disease in veterans with incident diabetes mellitus. *PLoS ONE*. 2018 Feb 9;13(2):e0192712–2.

67. Nyoman I, Swartawan I, Wayan N, Wardani S. Profil pasien penyakit ginjal kronis non dialisis di poli ginjal dan hipertensi RSUD Sanjiwani Gianyar. *Intisari Sains Medis | Intisari Sains Medis*. 2025;16(1):167–73
68. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control. *Circulation*. 2016 Aug 9;134(6):441–50.
69. Tedla FM, Brar A, Browne R, Brown C. Hypertension in Chronic Kidney Disease: Navigating the Evidence. *International Journal of Hypertension* [Internet]. 2011;2011:1–9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124254/>
70. Johnson RJ, Sanchez Lozada LG, Lanaspá MA, Piani F, Borghi C. Uric Acid and Chronic Kidney Disease: Still More to Do. *Kidney International Reports*. 2022 Dec;8(2).
71. Piani F, Sasai F, Bjornstad P, Borghi C, Yoshimura A, Sanchez-Lozada LG, et al. Hyperuricemia and chronic kidney disease: to treat or not to treat. *Brazilian Journal of Nephrology*. 2021 Mar 5;
72. Nivedita, Kumar A, Sinha A, Mitra JK, Sinha R. Uric acid levels in chronic kidney disease- a hospital based cross-sectional study in RIMS, Ranchi, Jharkhand. *International Journal of Research in Medical Sciences*. 2021 Jan 29;9(2):569.
73. Erdem E, Ozdemir A, Kaya C, Karatas A, Cengiz K. 2012. Serum Uric Acid Levels in Chronic Kidney Disease. *Firat Med J*.17(1):23–27

74. Kalantar-Zadeh K, Ficociello LH, Bazzanella J, Mullan C, Anger MS. Slipping Through the Pores: Hypoalbuminemia and Albumin Loss During Hemodialysis. *International Journal of Nephrology and Renovascular Disease* [Internet]. 2021;14:11–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/33505168/>
75. US-DOPPS (Dialysis Outcomes and Practice Patterns Study) Practice Monitor. Serum albumin (3 month average), categories; 2020.
76. Said EA, Al-Reesi I, Al-Shizawi N, Jaju S, Al-Balushi MS, Koh CY, et al. Defining IL-6 levels in healthy individuals: A meta-analysis. *Journal of Medical Virology*. 2021 Jun 1;93(6):3915–24.
77. Kreiner FF, Kraaijenhof JM, von Herrath M, Hovingh GKK, von Scholten BJ. Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. *Expert Review of Clinical Immunology*. 2022 Mar 1;18(4):377–89.
78. Aksungar FB, Topkaya AE, Akyildiz M. Interleukin-6, C-reactive protein and biochemical parameters during prolonged intermittent fasting. *Annals of Nutrition & Metabolism*. 2007;51(1):88–95.
79. Almeneessier AS, BaHamam AA, Alzoghaibi M, Olaish AH, Nashwan SZ, BaHamam AS. The effects of diurnal intermittent fasting on proinflammatory cytokine levels while controlling sleep/wake pattern, meal composition and energy expenditure. Oster H, editor. *PLOS ONE*. 2019 Dec 10;14(12):e0226034.

80. Abdullah, Kurnia FJ, Dharma Lm Desi S, Muhsin, Andri BK, et al. Declining in estimated glomerular filtration rate of chronic kidney disease patients after Ramadan fasting is independent of interleukin-6 serum level. *Bali medJ*. 2022 Jun 12(1): 94-98.
81. Chebotareva N, Vinogradov A, Gindis A, Tao E, Moiseev S. Heat shock protein 90 and NFkB levels in serum and urine in patients with chronic glomerulonephritis. *Cell Stress and Chaperones*. 2020 Apr 2;25(3):495–501.
82. Rojas-Morales P, Tapia E, León-Contreras JC, González-Reyes S, Jiménez- Osorio AS, Trujillo J, et al. Mechanisms of Fasting-Mediated Protection against Renal Injury and Fibrosis Development after Ischemic Acute Kidney Injury. *Biomolecules*. 2019 Aug 22;9(9):404.

